We would love to hear your thoughts about our site and services, please take our survey here.
The last CLN issue was done at an 80% premium to the share price in March 2019.
Share was approx 1.2p and CLN's 2p.
Whilst I do not expect this to happen again the 7 day VWAP would be reasonable and possibly why the SP has been pushed down.
Also under US tax law does Michaels conversion draw a tax charge and he needs to sell a few 100k to pay this.
From the August RNS, no cost to the company it would appear. But I assume no benefit either financially which is as it should be.
"The FDA allows for cost recovery in EAPs. As an unapproved agent, patients would have to incur these costs."
Does the company have the option of repaying the CLN amount plus interest if funds allow.
It would be better for TB to convert which is why he needs the wiggle room.
Just a thought but would welcome some feedback if anybody knows.
Did you even read the link Kane put up on the thread.
Healio got the RPD based on pre clinical studies in mice not phase 2 or 3 trials, this now QUALIFIES them for the PRV. what would be the point in a voucher that only becomes available once you have spent 100m to get to phase 3.
The buying has been strong today. I have sold 800k today as IQAI was getting up to 50% of my sipp which was not sensible.
Without this I am sure we would have hit or exceeded 6p.
So apologies but still holding a large amount and will not be selling.
Hi Alanadale
A single intravenous injection of 0.1 mL GADOVIST 1.0/kg body weight is recommended for most indications. A total amount of 0.3 mL GADOVIST 1.0/kg body weight may be administered at maximum.
Costs around $6 per 1ml, so between 60 and 180 dollars depending on weight and dosage.
if we say the average is 100 dollars then its a $50 saving (x millions of scans) the goal of zero G would also be in not having to administer, as needs a trained member of staff.
Only what I found on the web so Trek may have better information
To me a "step change" signifies cash flow positive in H2.
One last CLN to accelerate growth is perfectly acceptable to me as it would not be lights on funding. I still own over 2% of the company and will look to increase once expansion funding is sorted.
Reposted as removed
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111489/#:~:text=We%20classified%20an%20orphan%20indication,diseases%20were%20classified%20as%20pediatric.
Just one of the orphan drugs given pediatric status
How much does blinatumomab cost per cycle?
Amgen has just announced that blinatumomab (Blincyto) will cost about $178,000, making it one of the most expensive oncology drugs on the market. In a report from Reuters , an Amgen spokeswoman said the price reflected two courses of treatment, at $89,000 per cycle
Https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111489/#:~:text=We%20classified%20an%20orphan%20indication,diseases%20were%20classified%20as%20pediatric.
Very well done to all the team at IQAI looking ahead both fields can and will benefit a great deal of patients.